In this review, we aim to discuss the current knowledge of processes driving INPP5D transcription, the actions of its gene product SHIP1 in microglia and their relevance to AD, while examining its potential as a novel therapeutic target for Alzheimer’s disease. This evidence concerns the gene INPP5D and early-onset autosomal dominant Alzheimer disease.